Group releases new CLL guidelinesAugust 12, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Insurance status linked to survival in FL patientsAugust 11, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Team recommends melanoma screening in CLLAugust 10, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Frequent BCCs linked to blood cancersAugust 9, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersHodgkin LymphomaNon-Hodgkin LymphomaAggressive Lymphomas
FDA approves mogamulizumab for MF, SSAugust 8, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Treatment guidelines for CAR T-cell therapyAugust 7, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPediatricsALLNon-Hodgkin LymphomaAggressive Lymphomas
Company narrows focus of development for tazemetostatAugust 5, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Treatment improves PFS in early stage FLAugust 2, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Adult CCSs report financial hardshipsAugust 2, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPediatricsALLHodgkin LymphomaNon-Hodgkin LymphomaAggressive Lymphomas
Global burden of hematologic malignanciesJuly 29, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaAMLALLHodgkin LymphomaCML
Drug receives fast track designation for WMJuly 26, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
FDA approves biosimilar filgrastimJuly 22, 2018AnemiaLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaTransplantationAMLALL
Diabetics have higher risk of hematologic, other cancersJuly 20, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaAMLALLHodgkin LymphomaCML
PET-guided treatment didn’t improve outcomesJuly 16, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Health Canada expands approval of obinutuzumabJuly 10, 2018Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
